We read with great interest the recent prospective study by Dukewich et al., which demonstrated that longitudinal changes in specific cardiometabolic risk factors (CMRFs), particularly hemoglobin A1c and body weight, were strongly associated with clinically meaningful changes in liver stiffness measurement (LSM) and the controlled attenuation parameter (CAP) among adults with metabolic dysfunction–associated steatotic liver disease (MASLD)[1].
Journal of Hepatology published a clinical update in Research Highlights on 12 Mar 2026.
The item focuses on Systemic assessment via Cardiovascular-Kidney-Metabolic (CKM) staging complements the longitudinal evaluation of liver stiffness in MASLD.
Review the original article for the full source wording and details.